. 2022 Sep 1;38(Suppl 1):31–40. doi: 10.15605/jafes.037.S8

Table 2.

Allelic characterization of variants associated with poor gliclazide response

SNP	Implicated gene	Risk allele	Frequency		p-value^*	q-value^*	Predicted effect	Predicted Impact
SNP	Implicated gene	Risk allele	Cases	Controls	p-value^*	q-value^*	Predicted effect	SIFT	PolyPhen
rs2229437	PRCP	G	0.4444	0.2076	0.003247	1	Missense (E/D)	0.02 (deleterious)	0.009 (benign)
rs319952	AGBL4	A	0.8824	0.6504	0.005649	1	Intron variant	n/a
rs393994	AGBL4	A	0.8611	0.6525	0.012310	1	Intron variant	n/a
rs9806699	ENSG00000259354// C15ORF48	G	0.6389	0.4025	0.010840	1	5-upstream variant	n/a
rs7119	HMG20A	A	0.5	0.2585	0.005146	1	3' untranslated region	n/a
rs6465084	GRM3	A	1	0.8475	0.006797	1	Intron variant	n/a

Abbrev: PRCP, prolylcarboxypeptidase; AGBL4, ATP/GTP binding protein like 4; TNFSF4, TNF superfamily member 4; HMG20A, high mobility group 20A; GRM3, glutamate metabotropic receptor 3; E/D, glutamic acid (E) to aspartic acid (D) mutation; SIFT, Sorting Intolerant Form Tolerant; Polyphen, Polymorphism Phenotyping.

Variants are nominally significant at p<0.05.